FDA
-
-
-
-
-
-
-
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
-
-
-
-
-
-
-
CytomX Therapeutics (CTMX) Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
-
-
-
-
-
-
-
Pre-Open Movers 03/24: (GSAT) (NVAX) (CTMX) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
-
-
-
-
-
-
-
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
-
-
-
-
-
-
328,147 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

